{"filings":[{"id":2006243,"accession_number":"0001192448-26-000002","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-08-03T11:00:21+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files investor presentation; no material new information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exhibit 99.1 is an investor presentation dated August 2026; only disclaimer text provided.","No financial results, guidance, or product updates are disclosed in the filing excerpt.","The filing is a routine Regulation FD disclosure for investor materials.","No material changes to the company's business or outlook are indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1940720,"accession_number":"0001193125-26-323729","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-07-29T20:10:17+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q2 net sales $185.6M (+50% YoY); raises FY2026 guidance to $680-700M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales $185.6M, up 50% YoY; U.S. glaucoma sales $118.5M (+64%).","GAAP net loss $18.4M ($0.31/sh); non-GAAP net loss $8.3M ($0.14/sh), improved from $19.7M loss a year ago.","Gross margin 82% (non-GAAP 85%), up from 78% (83%) YoY.","Raised 2026 net sales guidance to $680-700M from prior $620-635M.","Cash $289.3M, no debt; cites iDose TR and Epioxa as growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":835998,"accession_number":"0001193125-26-255758","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-06-03T21:12:42+00:00","items":["5.07"],"status":"ready","headline":"Glaukos shareholders elect two Class II directors; approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Denice M. Torres: 40,843,317 for, 11,169,168 withheld (3,024,243 broker non-votes).","Aimee S. Weisner: 49,397,952 for, 2,614,533 withheld (3,024,243 broker non-votes).","Advisory vote on executive compensation: 47,653,794 for, 4,272,830 against, 85,861 abstain.","Ratification of Ernst & Young as auditor: 54,476,088 for, 515,703 against, 44,937 abstain; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91716,"accession_number":"0001193125-26-202466","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files 8-K to announce investor presentation; no material new data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["The 8-K states the investor presentation (Exhibit 99.1) will be used in meetings with investors and stakeholders.","No specific financial or operational updates are disclosed in the filing itself.","The presentation is available on the company's investor relations website as of May 4, 2026.","Exhibit 99.1 text is incomplete in the provided filing, preventing further summary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91715,"accession_number":"0001193125-26-191553","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales $150.6M (+41% YoY, +39% constant currency).","U.S. Glaucoma net sales $93.5M (+58% YoY); Glaucoma total $129.3M (+47% YoY).","GAAP net loss ($0.34)/share; non-GAAP net loss ($0.18)/share; operating loss narrowed YoY.","FY2026 net sales guidance raised to $620-635M from prior $600-620M.","Cash $280.5M, no debt; GAAP gross margin ~78%, non-GAAP ~84%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":150571000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101978,"accession_number":"0001104659-26-021885","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos posts Q4 2021 investor presentation with no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made available a March 2026 investor presentation via 8-K Item 7.01.","Presentation available on company website; no earnings or guidance provided.","No specific financial results, product updates, or strategic changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101977,"accession_number":"0001104659-26-016410","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.","GAAP net loss $133.7M ($2.32/sh) includes $112.9M non-cash impairment on Avedro intangible.","Non-GAAP net loss improved to $16.4M ($0.28/sh) from $22.2M ($0.40) in Q4 2024.","U.S. Glaucoma sales record $86.4M, +53% YoY; strong growth from iDose TR.","Ended Q4 with $282.6M cash, no debt; 2026 revenue guidance reaffirmed at $600-620M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":507442000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101976,"accession_number":"0001104659-26-003321","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).","U.S. Glaucoma net sales FY2025 $299M, including iDose TR $136M; Corneal Health $86M.","Cash & equivalents $283M, no debt at Q4 end; 2026 revenue guidance reaffirmed $600-620M.","International Glaucoma net sales FY2025 $122M; Q4 alone ~$33M.","Company will report full Q4 & FY2025 results on Feb 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":507442000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118320,"accession_number":"0001104659-25-108796","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files 8-K furnishing November 2025 investor presentation; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated November 2025 is furnished under Regulation FD and will be used in meetings.","No specific financial results, guidance, or corporate events were announced in the filing or attached exhibit.","The exhibit text is incomplete beyond a standard disclaimer; no new material facts are available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118319,"accession_number":"0001104659-25-103722","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q3 revenue $133.5M (+38% YoY); raises 2025 guide, introduces 2026 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales $133.5M, up 38% YoY; U.S. Glaucoma sales $80.8M (+57% YoY).","GAAP net loss $16.2M (($0.28)/share) improved from $21.4M loss prior year; non-GAAP loss $9.2M (($0.16)/share).","Raised FY2025 net sales guidance to $490-495M (from $480-486M); introduced preliminary FY2026 guidance $600-620M.","Gross margin ~78% (non-GAAP ~84%); ended quarter with $277.5M cash, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":364321000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134762,"accession_number":"0001558370-25-011142","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos posts investor presentation for August 2025; no specific financial updates visible","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation dated August 2025 made available via SEC filing and company website.","Presentation content is not provided in the filing excerpt; no new numbers or guidance are disclosed.","Presentation will be used in meetings with investors and stakeholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134761,"accession_number":"0001558370-25-009798","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q2 record net sales $124.1M (+30% YoY); raises FY 2025 guidance to $480-486M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales $124.1M, up 30% YoY; glaucoma sales $103.5M (+36%), U.S. glaucoma $72.3M (+45%).","Net loss narrowed to $19.7M ($0.34 per share) from $50.5M ($1.00); non-GAAP loss $13.6M ($0.24).","Gross margin ~78%, non-GAAP ~83%; cash & investments $278.6M, zero debt.","Raised 2025 net sales guidance to $480-486M (prior $475-485M); management cites sustained growth acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":230784000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151672,"accession_number":"0001558370-25-008365","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Glaukos stockholders elect directors, approve say-on-pay, ratify EY at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors Foley, Hoffmeister, and Kliman; broker non-votes of 3,221,029.","Advisory vote on NEO compensation approved: 48,971,169 for, 1,143,789 against, 57,534 abstain.","Ratified Ernst & Young as auditor for FY2025: 53,222,095 for, 140,642 against, 30,784 abstain, no broker non-votes.","Meeting held May 29, 2025; all three management proposals passed as recommended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151671,"accession_number":"0001558370-25-007647","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files routine investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed Form 8-K with an investor presentation dated May 2025.","Presentation content not provided in filing; only disclaimer page available.","No financial results, operational updates, or guidance changes disclosed.","Presentation intended for use in investor meetings, no new material events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151670,"accession_number":"0001558370-25-005999","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q1 net sales record $106.7M (+25% YoY); net loss narrows to $0.32/sh from $0.82","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 net sales $106.7M, up 25% reported and 26% constant currency vs $85.6M last year.","U.S. Glaucoma sales $59.1M (+41% YoY); total Glaucoma $88.1M (+31% YoY).","GAAP net loss $18.1M ($0.32/sh) vs $40.8M ($0.82/sh) in Q1 2024; non-GAAP net loss $12.6M ($0.22).","Gross margin ~77%; non-GAAP gross margin ~82%; operating loss improved to $20.7M from $39.1M.","Reaffirmed FY 2025 net sales guidance of $475M-$485M; cash $303.4M with no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":106664000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170520,"accession_number":"0001558370-25-002745","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos posts March 2025 investor presentation; no specific updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation filed under Item 7.01 Regulation FD; no earnings or guidance included.","No quantitative financial data, product milestones, or strategic changes provided in the exhibit.","Presentation contains forward-looking statements and standard disclaimers only.","Ticker GKOS; no new material facts for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170519,"accession_number":"0001558370-25-001217","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q4 record net sales $105.5M, +28% YoY; guides FY2025 $475-485M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales record $105.5M, +28% YoY; glaucoma segment $84.1M (+39%).","GAAP net loss ($0.60)/share vs ($0.75) prior year; non-GAAP net loss ($0.40).","FY 2024 net sales $383.5M (+22% YoY); net loss $146.4M ($2.77/share).","Cash $324M, no debt; 2025 revenue guidance $475-485M.","Q4 GAAP gross margin 73%; non-GAAP gross margin 82%."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":383481000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170518,"accession_number":"0001558370-25-000201","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files January 2025 investor presentation; no specific new data disclosed in excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing under Item 7.01 for Regulation FD; presentation to be used in investor meetings.","Exhibit 99.1 is a January 2025 investor presentation, but only disclaimer text is provided.","No financial metrics, strategic updates, or forward-looking statements are available from the attached exhibit.","Presentation available on company website; typical boilerplate disclosure without material new content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187523,"accession_number":"0001558370-24-016082","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Glaukos receives $53.2M from capped call unwind on convertible notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Option counterparties paid $53.2M to Glaukos under Capped Call Unwind Agreements.","Payment based on VWAP of common stock from Dec 3-5, 2024.","Unwind relates to 50% of shares underlying $287.5M 2.75% Convertible Senior Notes due 2027.","Agreements executed on Dec 2, 2024; cash delivered post-averaging period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187522,"accession_number":"0001558370-24-015973","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Glaukos partially unwinds capped calls on 2027 convertible notes; receives cash based on VWAP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into unwind agreements for 50% of capped call transactions associated with $287.5M 2.75% convertible notes due 2027.","Cash settlement amount determined by VWAP of common stock over averaging period starting Dec 3, 2024.","Early termination of portion of capped calls reduces dilution protection but provides immediate cash to Glaukos.","Unwind agreements executed Dec 2, 2024 with multiple financial institution counterparties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187521,"accession_number":"0001558370-24-015776","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files routine investor presentation for November 2024; no specific new data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an investor presentation dated November 2024 under Regulation FD.","Presentation available on company website; no material changes or guidance disclosed.","Exhibit text truncated; specific financial or strategic details not provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187520,"accession_number":"0001558370-24-014262","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).","GAAP net loss narrowed to $21.4M ($0.39 loss per share) from $30.4M ($0.63) in Q3 2023.","Non-GAAP net loss $15.2M ($0.28 per share) vs $24.2M ($0.50) prior year.","Raised FY2024 net sales guidance to $377M-$379M from prior $370M-$376M.","Gross margin ~77%, non-GAAP ~82%; ended quarter with $267.2M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":277982000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187519,"accession_number":"0001558370-24-013262","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Glaukos redeems all $57.5M of 2.75% Convertible Notes due 2027; conversion by Dec 13, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company issued notice to redeem all $57.5M aggregate principal of 2.75% Convertible Senior Notes due 2027.","Redemption date December 16, 2024; redemption price at 100% of principal plus accrued interest from Dec 1, 2024.","Holders may convert notes into common stock at 18.1770 shares per $1,000 principal until Dec 13, 2024.","Notes originally issued in June 2020; redemption exercised under indenture terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204009,"accession_number":"0001558370-24-011675","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos provides investor presentation; no material new facts in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated August 2024; full content not available in provided text.","Filing is routine Regulation FD disclosure; no guidance or financial results announced.","Presentation to be used in investor meetings; available on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204007,"accession_number":"0001558370-24-010731","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K/A","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glaukos files 8-K/A to correct $3.3M debt cost accounting; GAAP EPS overstated by $0.06","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected reclassification of $3.3M unamortized debt issuance costs from interest expense to additional paid-in capital for the June 2024 convertible note exchange.","GAAP net loss for Q2 2024 restated to $50.5M (was $53.8M as originally reported); per share impact $0.06.","GAAP EPS corrected to ($1.00) for Q2 and ($1.82) for H1 2024; originally reported as ($1.06) and ($1.89).","Non-GAAP results unchanged; revised financials filed in 10-Q and updated on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204008,"accession_number":"0001558370-24-010478","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.","Glaucoma segment sales $75.9M (+23% YoY); Corneal Health $19.8M (+7% YoY).","GAAP net loss $53.9M ($1.06 loss per share) vs $32.8M ($0.68) in Q2 2023.","Non-GAAP net loss $26.3M ($0.52 loss per share) improved from $26.6M ($0.55) prior year.","FY2024 net sales guidance raised to $370M–$376M from $357M–$365M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":181312000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220695,"accession_number":"0001104659-24-076328","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Glaukos exchanges $230M of 2.75% convertible notes for 4.25M shares of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged $230M principal of 2.75% Convertible Senior Notes due 2027 for 4,253,423 common shares and cash.","Exchange was done via privately negotiated agreements with qualified institutional buyers and accredited investors.","Transaction closed June 28, 2024; reduces debt by $230M and adds 4.25M shares to outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220694,"accession_number":"0001558370-24-009169","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Glaukos exchanges $230M of 2.75% Convertible Notes due 2027 for common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Glaukos entered agreements to repurchase $230M of its 2.75% Convertible Senior Notes due 2027.","Consideration will be shares of common stock, determined over an averaging period starting June 14, 2024, plus cash for fractional shares and accrued interest.","Transaction is expected to close on or about June 25, 2024, subject to customary conditions.","Shares issued will be unregistered and sold only to QIBs and institutional accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220693,"accession_number":"0001558370-24-008913","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Glaukos stockholders approve amended 2015 omnibus incentive plan; directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended and Restated 2015 Omnibus Incentive Plan, reducing share reserve to 4.7M new shares plus rollover of outstanding awards.","Plan eliminates evergreen feature, prohibits repricing without stockholder approval, extends term to May 30, 2034.","Class III directors Thomas W. Burns, Marc A. Stapley, and Leana S. Wen elected with over 35M votes each.","Advisory say-on-pay passed with 43.2M for vs 1.95M against; say-on-frequency favored one year with 44.2M votes.","Ernst & Young ratified as independent auditor for FY2024 (47.5M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220692,"accession_number":"0001558370-24-008440","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos furnishes May 2024 investor presentation with no specific financial updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a standard investor presentation as Exhibit 99.1; no new financial results or guidance disclosed.","Presentation will be available on the company's investor relations website.","No material changes to business outlook, strategy, or operations were announced in the filing.","Filing is a routine Regulation FD disclosure; no earnings, M&A, or operational events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220691,"accession_number":"0001558370-24-006383","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).","GAAP gross margin 76%; non-GAAP gross margin 83%.","GAAP net loss per share ($0.82); non-GAAP net loss per share ($0.70) includes $11.7M IPR&D charge.","Raised 2024 net sales guidance from $350-$360M to $357-$365M.","Cash and investments ~$279M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":85622000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240310,"accession_number":"0001558370-24-001912","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos makes investor presentation available; no material new facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an investor presentation dated February 2024 on its website.","Presentation attached as Exhibit 99.1 to Form 8-K filed February 28, 2024.","Filing contains only boilerplate FD disclosure; no specific financial or operational updates provided in the exhibit text excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240309,"accession_number":"0001558370-24-001431","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos reports record Q4 net sales $82.4M, up 16% YoY; FY2023 sales $314.7M, up 11%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 2023 net sales $82.4M, up 16% YoY; glaucoma $60.6M (+15%), corneal health $21.8M (+19%).","Q4 GAAP net loss $36.8M ($0.75/share) vs $31.5M ($0.66) YoY; non-GAAP loss $30.6M ($0.63).","Full-year 2023 net sales $314.7M, up 11% YoY; net loss $134.7M ($2.78/share) vs $99.2M ($2.09) in 2022.","Ended Q4 with $301M cash, equivalents & short-term investments; reaffirmed 2024 net sales guidance $350M-$360M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":314711000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240308,"accession_number":"0001558370-24-000141","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos reports preliminary Q4 2023 net sales >$81M, FY >$313M; reaffirms 2024 guidance $350-360M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 net sales exceeded $81 million.","Preliminary full-year 2023 net sales exceeded $313 million.","Reaffirmed 2024 net sales guidance of $350M to $360M.","Results are unaudited and subject to final adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":314711000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257813,"accession_number":"0001104659-23-125872","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos receives FDA approval for iDose TR; 2024 revenue guidance $350-$360M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved iDose TR (travoprost intracameral implant) for reducing IOP in OHT or OAG; launch expected late Q1 2024.","Phase 3 trials randomized 1,150 subjects; iDose TR showed non-inferiority to timolol at 3 months (IOP reduction 6.6-8.4 mmHg).","81% of iDose TR subjects were free of topical IOP-lowering medications at 12 months; 98% subject retention at 12 months.","Wholesale acquisition cost set at $13,950 per implant; Glaukos launches iDose Your Dose charitable donation initiative.","Reaffirms 2023 net sales guidance of $307-$310M; introduces 2024 preliminary guidance of $350-$360M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257812,"accession_number":"0001558370-23-017235","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q3 net sales up 10% to $78M; raises FY2023 guidance to $307-310M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $78.0M (+10% YoY); glaucoma $58.3M (+9%), corneal health $19.7M (+12%).","GAAP net loss $30.4M ($0.63/share); non-GAAP net loss $24.2M ($0.50/share).","Raised FY2023 net sales guidance to $307-310M from $304-308M.","Cash and equivalents $307M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":232346000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275171,"accession_number":"0001558370-23-015089","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos furnishes August 2023 investor presentation; no specific data in exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed under Regulation FD; exhibit text only contains a standard disclaimer.","Full presentation is available on Glaukos' investor relations website.","No financial metrics, product updates, or guidance changes are included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275170,"accession_number":"0001558370-23-012911","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q2 net sales up 11% to $80.4M; raises FY2023 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $80.4M, +11% YoY; glaucoma sales $61.9M (+10%), corneal health $18.5M (+11% YoY).","GAAP net loss per diluted share ($0.68) vs ($0.96) in Q2 2022; non-GAAP loss per share ($0.55) vs ($0.83).","Gross margin ~75%; non-GAAP gross margin ~82%; cash and investments $310M at quarter-end.","2023 net sales guidance raised to $304-308M from $295-300M previously.","Operating loss narrowed to $29.1M from $36.8M; SG&A +6% to $53.1M, R&D +5% to $33.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":154298000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292588,"accession_number":"0001558370-23-010858","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Glaukos stockholders elect Torres and Weisner as Class II directors; ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two Class II directors elected: Denice M. Torres (29,021,555 for; 11,852,403 withheld) and Aimee S. Weisner (39,492,847 for; 1,381,111 withheld).","Non-binding advisory vote on executive compensation approved: 37,101,296 for, 3,742,568 against, 30,094 abstain.","Ratification of Ernst & Young as independent auditor for 2022 approved: 43,725,937 for, 145,925 against, 21,838 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292587,"accession_number":"0001558370-23-010076","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos makes May 2023 investor presentation available; no specific new data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed investor presentation dated May 2023 for use in stakeholder meetings.","Presentation available on investor page of Glaukos website; no financial updates provided in this filing.","Item 7.01 disclosure; information furnished not filed, per SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292586,"accession_number":"0001558370-23-007832","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q1 net sales rise 9% to $73.9M; guides 2023 sales up; GAAP net loss widens to $34.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 net sales $73.9M (+9% YoY); glaucoma $56.2M (+9%), corneal health $17.7M (+10%).","GAAP net loss $34.6M ($0.72 loss per share) vs net income $5.4M ($0.11) in Q1 2022.","Non-GAAP net loss $28.4M ($0.59) vs prior-year non-GAAP net loss $18.1M ($0.38).","Raised 2023 net sales guidance to $295-300M from $290-295M.","Operating expenses increased sharply: SG&A +22%, R&D +31%; ended Q1 with $325M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":73899000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313247,"accession_number":"0001558370-23-002473","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos furnishes March 2023 investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an investor presentation under Item 7.01 Regulation FD Disclosure.","Presentation is dated March 2023 and will be used in meetings with investors and stakeholders.","No specific financial results, guidance, or material events were disclosed in the filing.","Presentation is available on the company's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313246,"accession_number":"0001558370-23-001767","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q4 net sales $71.2M, down 3% YoY; full-year net loss $99.2M; guides 2023 sales $290-295M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $71.2M (-3% YoY); glaucoma $52.9M, corneal health $18.3M.","Q4 GAAP net loss $31.5M ($0.66/sh); non-GAAP net loss $25.1M ($0.53/sh).","Full-year 2022 net sales $282.9M (-4% YoY); net loss $99.2M ($2.09/sh).","2023 net sales guidance $290M-$295M; cash & equivalents $360M.","R&D expenses rose 34% in Q4 to $35.8M; SG&A up 9% to $51.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":282862000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313245,"accession_number":"0001558370-23-000185","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos furnishes January 2023 investor presentation; no material new information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed under Item 7.01 as Exhibit 99.1 on January 10, 2023.","Exhibit contains only standard forward-looking statements and risk factors; no financial data or operational updates.","No earnings, guidance, M&A, or other material events disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331776,"accession_number":"0001558370-22-018893","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Glaukos amends Bylaws to incorporate universal proxy rules and update advance notice provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendments adopt SEC Rule 14a-19 universal proxy requirements into advance notice provisions for director nominations.","Stockholders must provide evidence of compliance with universal proxy rules within 5 business days before the meeting.","New provisions require nominees to agree to serve full term if elected, and permit Board interviews of proposed nominees.","Other updates align adjournment procedures and stockholder list requirements with recent Delaware General Corporation Law amendments.","Proxy card color reserved for Board use; stockholders soliciting proxies must use a different color."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331775,"accession_number":"0001558370-22-017915","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files November 2022 investor presentation; no material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Routine investor presentation furnished under Item 7.01, not filed.","No specific financial results or forward-looking guidance provided in the filing text.","Presentation content not fully available; no material events identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331774,"accession_number":"0001558370-22-015982","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q3 net loss $27.6M ($0.58 EPS); revenue down 4.6% YoY to $71.3M; raises 2022 sales outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $71.3M, down 4.6% reported (1.6% constant currency) vs $74.7M in Q3 2021.","Net loss $27.6M ($0.58 diluted) vs net income $6.2M ($0.13) in prior year, which included $30M litigation settlement.","Non-GAAP net loss $21.3M ($0.45) vs non-GAAP net loss $14.7M ($0.31) in Q3 2021.","Updated 2022 net sales guidance to $278-280M from prior $275-280M; cash and investments $371M.","Glaucoma net sales $53.7M, Corneal Health $17.5M; GAAP gross margin 76%, non-GAAP 84%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":211635000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349253,"accession_number":"0001558370-22-014218","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glaukos files investor presentation for September 2022; no specific figures disclosed in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished a new investor presentation (Exhibit 99.1) dated September 2022.","Presentation will be used in meetings with investors and other stakeholders.","No quantitative details or material updates are visible from the filing excerpt.","Presentation is available on the company's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349252,"accession_number":"0001558370-22-011887","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glaukos Q2 net sales $72.7M, down 7% YoY; raises FY2022 guidance to $275-280M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $72.7M in Q2 2022, down 7% YoY; glaucoma $56.1M, corneal health $16.6M.","GAAP net loss of $45.5M ($0.96 EPS) vs loss of $17.5M ($0.38) in Q2 2021; includes $10M IPR&D charge for iVeena licensing.","Non-GAAP net loss of $39.1M ($0.83) vs $10.1M ($0.22) in prior year.","Raised 2022 net sales guidance to $275-280M from prior $270-275M.","Ended Q2 with ~$400M cash and short-term investments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":140366000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366147,"accession_number":"0001558370-22-009821","cik":1192448,"company_name":"GLAUKOS Corp","ticker":"GKOS","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Glaukos shareholders elect three Class I directors at June 2 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mark J. Foley, David F. Hoffmeister, and Gilbert H. Kliman elected as Class I directors with 29.96M, 31.03M, and 30.48M votes for respectively.","Advisory vote on executive compensation approved: 36.80M for, 2.72M against, 33K abstain.","Ratification of Ernst & Young as independent auditor for 2022 passed: 42.61M for, 279K against, 80K abstain.","No broker non-votes on auditor ratification; 3.41M broker non-votes on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6481580432.364671,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-08T23:59:59+00:00|366147"}